Sign up to save your podcasts
Or
Share Takayuki Yoshino on the DESTINY-CRC01 trial
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Takayuki Yoshino on the DESTINY-CRC01 trial
Takayuki Yoshino (National Cancer Center Hospital East, Kashiwa, Japan) discusses the DESTINY-CRC01 trial on trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer.
Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00086-3/fulltext
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
View all episodes
By The Lancet Group
5
11 ratings
Takayuki Yoshino (National Cancer Center Hospital East, Kashiwa, Japan) discusses the DESTINY-CRC01 trial on trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer.
Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00086-3/fulltext
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
More shows like The Lancet Oncology in conversation with
View all
Global News Podcast
7,586 Listeners
JAMA Editors' Summary
136 Listeners
NEJM This Week
317 Listeners
JAMA Clinical Reviews
497 Listeners
Journal of Clinical Oncology (JCO) Podcast
40 Listeners
JCO Oncology Practice Podcast
17 Listeners
PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
12 Listeners
ASCO Daily News
58 Listeners
JAMA Oncology Author Interviews
11 Listeners
ASCO Guidelines
45 Listeners
ASCO Education
32 Listeners
JAMA Medical News
92 Listeners
The Lancet Voice
21 Listeners
The Lancet Child & Adolescent Health in conversation with
0 Listeners
The Lancet Digital Health in conversation with
0 Listeners
The Lancet Global Health in conversation with
2 Listeners
The Lancet Psychiatry in conversation with
0 Listeners
The Lancet Respiratory Medicine in conversation with
2 Listeners
The Lancet in conversation with
1 Listeners
The Lancet Haematology in conversation with
0 Listeners
The Lancet Gastroenterology & Hepatology in conversation with
0 Listeners
The Lancet Diabetes & Endocrinology in conversation with
1 Listeners
The Lancet Infectious Diseases in conversation with
1 Listeners
The Lancet Public Health in conversation with
1 Listeners
The Lancet Microbe in conversation with
0 Listeners
eBioMedicine in conversation with
0 Listeners
In conversation with...
0 Listeners
CNN This Morning
115 Listeners
Two Onc Docs
192 Listeners
Oncology Brothers: Practice-Changing Cancer Discussions
44 Listeners
The Lancet Rheumatology in conversation with
0 Listeners
The Lancet Regional Health in conversation with
0 Listeners
The Lancet Primary Care in conversation with
0 Listeners
The Lancet Regional Health Americas in conversation with
0 Listeners